Tandem CD19/CD22 CAR T-Cell Therapy: A Promising Advance for High-Risk Pediatric and AYA r/r B-ALL
Highlight
– Tandem CD19/CD22 CAR T-cell therapy achieved complete remission in 80% of heavily pretreated pediatric and young adult patients with r/r B-ALL at 28 days post-infusion.
– Combination with consolidative hematopoietic stem cell transplantation (HSCT) yielded an 18-month overall survival of 70%.
– High-grade cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) correlated with preinfusion high tumor burden (TB), emphasizing the need for effective bridging therapy.
Study Background and Disease Burden
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.